Coherus Oncology (CHRS) Operating Expenses (2013 - 2026)

Coherus Oncology has disclosed Operating Expenses across 14 years of filings, most recently posting $48.5 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $48.5 million, down 8.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $218.7 million (up 4.67% YoY), and the FY2025 annual result was $223.3 million, down 1.21% from the prior year.
• Operating Expenses came in at $48.5 million for Q1 2026 at Coherus Oncology, down from $58.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $160.4 million in Q4 2023 to a low of $48.5 million in Q1 2026.
• The 5-year median for Operating Expenses is $70.1 million (2024), against an average of $83.9 million.
• Across the five-year window, Operating Expenses surged 65.66% in 2023 and tumbled 66.89% in 2024, its largest moves.
• Coherus Oncology's Operating Expenses stood at $96.8 million in 2022, then jumped by 65.66% to $160.4 million in 2023, then sank by 66.89% to $53.1 million in 2024, then increased by 10.38% to $58.6 million in 2025, then fell by 17.34% to $48.5 million in 2026.
• The last three Operating Expenses figures came in at $48.5 million (Q1 2026), $58.6 million (Q4 2025), and $55.9 million (Q3 2025), per Business Quant data.